PMID- 22707303
OWN - NLM
STAT- MEDLINE
DCOM- 20130507
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 61
IP  - 12
DP  - 2012 Dec
TI  - Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted 
      cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay.
PG  - 2311-9
LID - 10.1007/s00262-012-1298-1 [doi]
AB  - Many cancer-testis antigen genes have been identified; however, few human 
      leukocyte antigen (HLA)-A24-restricted cytotoxic T cell (CTL) epitope peptides 
      are available for clinical immunotherapy. To solve this problem, novel tools 
      increasing the efficacy and accuracy of CTL epitope detection are needed. In the 
      present study, we utilized a highly active dendritic cell (DC)-culture method and 
      an in silico HLA-A24 peptide-docking simulation assay to identify novel CTL 
      epitopes from MAGE-A6 and MAGE-A12 antigens. The highly active DCs, called 
      alpha-type-1 DCs, were prepared using a combination of maturation reagents to produce 
      a large amount of interleukin-12. Meanwhile, our HLA-A24 peptide-docking 
      simulation assay was previously demonstrated to have an obvious advantage of 
      accuracy over the conventional prediction tool, bioinformatics and molecular 
      analysis section. For CTL induction assays, peripheral blood mononuclear cells 
      derived from six cases of HLA-A24(+) melanoma were used. Through CTL induction 
      against melanoma cell lines and peptide-docking simulation assays, two peptides 
      (IFGDPKKLL from MAGE-A6 and IFSKASEYL from MAGE-A12) were identified as novel CTL 
      epitope candidates. Finally, we verified that the combination of the highly 
      active DC-culture method and HLA-A24 peptide-docking simulation assay might be 
      tools for predicting CTL epitopes against cancer antigens.
FAU - Akiyama, Yasuto
AU  - Akiyama Y
AD  - Immunotherapy Division, Shizuoka Cancer Center Research Institute, 1007 
      Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. 
      y.akiyama@scchr.jp
FAU - Komiyama, Masaru
AU  - Komiyama M
FAU - Nakamura, Yoji
AU  - Nakamura Y
FAU - Iizuka, Akira
AU  - Iizuka A
FAU - Oshita, Chie
AU  - Oshita C
FAU - Kume, Akiko
AU  - Kume A
FAU - Nogami, Masahiro
AU  - Nogami M
FAU - Miyata, Haruo
AU  - Miyata H
FAU - Ashizawa, Tadashi
AU  - Ashizawa T
FAU - Yoshikawa, Shusuke
AU  - Yoshikawa S
FAU - Kiyohara, Yoshio
AU  - Kiyohara Y
FAU - Yamaguchi, Ken
AU  - Yamaguchi K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120616
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (MAGEA12 protein, human)
RN  - 0 (MAGEA6 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Peptides)
RN  - 187348-17-0 (Interleukin-12)
SB  - IM
MH  - Antigens, Neoplasm/*immunology/metabolism
MH  - Cell Line, Tumor
MH  - Dendritic Cells/immunology/metabolism
MH  - Epitopes, T-Lymphocyte/*immunology/metabolism
MH  - Female
MH  - HLA-A24 Antigen/*immunology/metabolism
MH  - Humans
MH  - Interleukin-12/immunology/metabolism
MH  - Leukocytes, Mononuclear/immunology/metabolism
MH  - Male
MH  - Melanocytes/immunology/metabolism
MH  - Melanoma/immunology/metabolism
MH  - Middle Aged
MH  - Neoplasm Proteins/*immunology/metabolism
MH  - Peptides/*immunology/metabolism
MH  - T-Lymphocytes, Cytotoxic/*immunology/metabolism
PMC - PMC11029329
COIS- The authors declare that they have no conflict of interest.
EDAT- 2012/06/19 06:00
MHDA- 2013/05/08 06:00
PMCR- 2012/06/16
CRDT- 2012/06/19 06:00
PHST- 2011/10/27 00:00 [received]
PHST- 2012/05/29 00:00 [accepted]
PHST- 2012/06/19 06:00 [entrez]
PHST- 2012/06/19 06:00 [pubmed]
PHST- 2013/05/08 06:00 [medline]
PHST- 2012/06/16 00:00 [pmc-release]
AID - 1298 [pii]
AID - 10.1007/s00262-012-1298-1 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2012 Dec;61(12):2311-9. doi: 
      10.1007/s00262-012-1298-1. Epub 2012 Jun 16.